Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in pneumoconiosis
NCT05288179Phase 3Recruiting
- Sponsor
- Gyre Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pirfenidone in pneumoconiosis, sponsored by Gyre Pharmaceuticals. Started Jun 2022; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
pneumoconiosis
Beyond the preview
Go deeper on NCT05288179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288179.